Can cancer vaccine with immunotherapy shrink liver tumor?

Published On 2024-04-27 02:30 GMT | Update On 2024-04-27 02:30 GMT

According to a study published in the journal Nature Medicine, people with Hepatocellular Carcinoma treated with immunotherapy and a personalized anti-tumor vaccine were twice as likely to experience tumor shrinkage compared to those receiving immunotherapy only.Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer and is a leading cause of cancer-related death...

According to a study published in the journal Nature Medicine, people with Hepatocellular Carcinoma treated with immunotherapy and a personalized anti-tumor vaccine were twice as likely to experience tumor shrinkage compared to those receiving immunotherapy only.

Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer and is a leading cause of cancer-related death worldwide. Despite recent advancements in systemic therapy for advanced HCC, the 5-year survival rate remains <10%. One of the newest treatment options for HCC is immunotherapy — a treatment using a person’s own immune system to fight the cancer. However, past studies show that only 15–20% of HCC diagnoses respond to immunotherapy and about 30% may be resistant.

In the study, researchers recruited 36 participants for the clinical trial. All participants received the combination of a personalized DNA vaccine, GNOS-PV02, and pembrolizumab.

At the end of the study, researchers found that almost one-third of participants experienced tumor shrinkage, which is about twice as many people seen in studies of immunotherapy alone for HCC. Additionally, about 8% of the study participants had no evidence of a tumor after receiving the combination treatment.

“The response rate on this study is high enough that I think it’s unlikely that the pembrolizumab alone did this and it supports the idea that the vaccine contributed to the efficacy observed. I think it’s also notable that the response rate was higher than pembrolizumab alone without a major increase in toxicity” said Mark Yarchoan, lead study author.

While further research is needed to validate these findings and optimize treatment protocols, the results of this phase 1/2 trial represent a significant step forward in the quest for more effective therapies for advanced hepatocellular carcinoma. With continued advancements in personalized immunotherapy, there is hope for transforming the landscape of cancer care and improving outcomes for patients facing this devastating disease.

Reference: Yarchoan, M., Gane, E.J., Marron, T.U. et al. Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial. Nat Med (2024). https://doi.org/10.1038/s41591-024-02894-y

Article Source : Nature Medicine

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Roshni Dhar

Roshni Dhar, a Mass com graduate with a soft corner for health happenings, joined Medical Dialogues as a news anchor in 2021. Inspired by her mother who is a gynaecologist, she likes to keep herself and the world updated on the occurring in the medical field. She covers various aspects of health news for MDTV at Medical Dialogues. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Can cancer vaccine with immunotherapy shrink liver tumor?

Similar News